Chison Medical released its 2026 interim report. Net profit attributable to the parent in the first half was 68.96 million yuan, down 1.1% year on year, while operating revenue was 241 million yuan, up 2.2% year on year. In the second quarter, operating revenue was 114 million yuan, up 5.3% year on year, and net profit attributable to the parent was 22.93 million yuan, down 18.3% year on year. As of the end of the second quarter, total assets were 1.602 billion yuan, up 0.5% from the end of the previous year, and net assets attributable to the parent were 1.368 billion yuan, down 1.1% from the end of the previous year. The company said overall operations remained stable. Despite external pressures such as trade frictions and supply chain restructuring, it showed strong operational resilience thanks to three decades of industry experience and a globalized footprint. In addition, the SonoMax series has obtained EU CE certification, China medical device registration, and US FDA market access approval.
Chison Medical Technologies Co LtdFirst-half net profit fell 1.1% year on year, with Q2 profit down 18.3%.
